Hemostatic Disorders clinical trials

The registry lists 361 studies for Hemostatic Disorders across more than 10 countries. 65 are recruiting or about to start. 139 of them are mainly about Hemostatic Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 8 narrower conditions too, such as Multiple Myeloma: 4,738 studies, 961 open.

Get an email when these change. Save the Hemostatic Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 195
Recruiting: 51
Status unknown: 49
Terminated: 29
Withdrawn: 16
Not yet recruiting: 12

Phase

Phase 3: 43
Phase 2: 37
Phase 4: 30
Phase 1: 28
Early Phase 1: 3

Where

United States: 106
France: 34
China: 25
Italy: 23
Canada: 20
United Kingdom: 17

Who runs them

BioMarin Pharmaceutical (8) · HemoSonics LLC (7) · Assiut University (7) · University Health Network, Toronto (4) · VarmX B.V. (4) · University Hospital, Motol (4) · Medical University of Graz (4) · Bayer (4)

What is being tested here

Drugs under test in Hemostatic Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Tranexamic Acid	2	0	3
Fibrinogen	1	2	14
Prothrombin complex concentrate	1	2	4
BAY 3389934	1	0	2
Ginger extract	1	0	2
Fibrinolysin	1	0	1
Dipyrone	1	0	1
Valoctocogene Roxaparvovec	0	4	7
Enoxaparin	0	2	4
Apixaban	0	0	3

Drug classes tested here Factor Xa inhibitors 6 · NSAIDs 5 · Corticosteroids 4

Coming up

3phase 3 studies under way

22studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Nov 2026Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation · University of Massachusetts, Worcester
Nov 2026Coagulopathy in Childhood Acute Lymphoblastic Leukaemia · Karolinska University Hospital
Nov 2026Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) · Duke University
Dec 2026A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · OriCell Therapeutics Co., Ltd.
Dec 2026Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study. · Centre Hospitalier Universitaire de Nīmes
Dec 2026A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy · Bayer
Dec 2026Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT） · Nanfang Hospital, Southern Medical University
Dec 2026Quantra Point-of-Care Hemostasis Monitoring · The Cleveland Clinic
Dec 2026Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients · Indiana University
Dec 2026Recombinant vWF Concentrate and ECMO · University of Virginia

Who these studies take

Of the 51 Hemostatic Disorders studies recruiting now, 32 (63%) set no upper age limit and 10 (20%) stop at 75 or younger. 18 (35%) take children under 18. 6 (12%) are for women only and 0 (0%) for men only; 13 (25%) take healthy volunteers.

Recruiting studies that take each age, of 51
Age	Women	Men
10	12 (24%)	10 (20%)
18	50 (98%)	44 (86%)
30	47 (92%)	43 (84%)
40	47 (92%)	43 (84%)
50	47 (92%)	43 (84%)
65	46 (90%)	42 (82%)
75	43 (84%)	39 (76%)
85	38 (75%)	34 (67%)

Across all 361 studies, recruiting or not: 20% stop at 75 or younger and 15% at 65; 21% take children; 6% are for women only and 5% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemostatic Disorders studies take

Of 19 phase 3 interventional studies under Hemostatic Disorders, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 3	33 mo21–46 · 19 studies	—	—
Interventional, no phase	22 mo13–40 · 33 studies	—	24 mo12–40 · 31 studies
Observational	24 mo9–56 · 108 studies	—	25 mo12–57 · 98 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Stopped1

Factor In the Initial Resuscitation of Severe Trauma 2 PatientsTerminatedOct 21, 2026NCT04534751

Newly registered2

Safety of Intraosseous Anaesthesia in Children With HaemophiliaNov 4, 2026NCT07916467
Innovative Approaches to Identify Causative Genetic Variants in Patients With Unexplained Bleeding DisordersOct 13, 2026NCT07870057

Studies

Recruiting first, then most recently updated. Showing 50 of 361. Browse all 361 → or search them.